Navigation Links
Celator(R) Pharmaceuticals Reports CPX-351 Shows Anti-Cancer Activity in Leukemia Patients
Date:12/10/2007

Results from ongoing Phase I study of advanced leukemia and myelodysplastic syndrome patients presented at American Society for Hematology meeting.

PRINCETON, N.J., Dec. 10 /PRNewswire/ -- Celator Pharmaceuticals today announced results from an ongoing Phase I study of CPX-351, a liposomal formulation that incorporates a synergistic ratio of cytarabine and daunorubicin for the treatment of advanced leukemias and myelodysplastic syndromes. While dose escalation in the study is ongoing, thus far three patients treated with CPX-351 have achieved complete remissions (CR), one patient has achieved a CRp (complete remission where platelets did not recover to greater than 100,000 platelets per microliter), and two additional patients achieved partial remissions (PR).

The study included patients with relapsed/refractory acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and high-risk myelodysplastic syndrome (MDS). All but three of the 27 patients had AML. The majority of patients were older than 60 years of age, including four patients older than 75. All patients had relapsed or refractory disease, with 15/27 having received two or more prior induction therapies. After their last therapy, 19/27 had no response and 8/27 achieved a CR. CPX-351 has been safely administered up to and including 101 units/m2 (=101 mg/m2 of cytarabine and 44mg/m2 of daunorubicin). Non-hematologic adverse events included stomatitis (10/27 patients), skin rash (10/27), diarrhea (9/27), nausea (7/27), vomiting (5/27) and alopecia (2/27). The study has shown that CPX-351 is capable of inducing marrow aplasia with few severe non-hematologic adverse events.

"CPX-351 is a provocative new treatment approach for patients with AML," said Eric Feldman, MD, from Weill Medical College of Cornell University and New York Presbyterian Hospital and an investigator in the Phase I study. "The data from the Phase I study in highly refractory AML patients are encouraging, includi
'/>"/>

SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2015)... Fla. , July 2, 2015  Fort ... is pleased to announce that its Consumer Group ... Beverages") to Kerry Group plc (ISE: KRZ) ("Kerry"), ... taste and nutrition systems, as well as functional ... and pharmaceutical markets. Farlie Turner served as the ...
(Date:7/2/2015)... June 26, 2015 Research and ... "Vitamin D Market by Analog, Application, End-User & by Region ... their offering. This market is projected to reach ... D in different applications and rising opportunities in countries such ... , Italy , and Brazil ...
(Date:7/2/2015)... Pharma Major Lupin Limited today announced the acquisition of ... subject to certain closing conditions. The acquisition marks ... 765 billion in sales, placing it as one of the ... Health). For over a decade, Russian pharmaceutical market recorded double ... Russia to be one of the ...
Breaking Medicine Technology:Farlie Turner's Consumer Group Completes Sale of Insight Beverages to Kerry 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 2Vitamin D Market by Analog, Application, End-User & by Region - Global Trends & Forecast to 2020: Increasing Recommendation By Doctors & Associations 3Lupin Acquires Biocom in Russia 2Lupin Acquires Biocom in Russia 3
... Pharmaceuticals, Inc. (Nasdaq: ISTA ), today announced it will ... November 3, 2009. In conjunction, the Company will host a ... results and provide a pipeline update. , Date: Tuesday, ... , Conference call access: , Internet: www.istavision.com ...
... Oct. 2 Massachusetts General Hospital (MGH) Cancer Center has ... Elekta Infinity and one Elekta Synergy® ... , will enable the facility to offer patients a ... Infinity systems position MGH to take ...
Cached Medicine Technology:Massachusetts General Hospital Selects Elekta As New Vendor for Complete Cancer Treatment Solution 2
(Date:7/3/2015)... Greenville, SC (PRWEB) , ... ... ... Society has announced the sessions and speaker lineup for its 2015 ... nursing, taking place August 6-8, 2015 at the Renaissance Orlando at SeaWorld ...
(Date:7/3/2015)... ... July 03, 2015 , ... Scientists at several top US cancer centers ... minimal asbestos exposure. Click here to read the complete story , just posted ... Center, Cedars Sinai Medical Center, and New York University exposed mice with a mutation ...
(Date:7/3/2015)... ... ... Renowned rhinoplasty surgeon and Symposium Chairman, Dr. Rod J. Rohrich , ... held from March 4th - 6th, the 2016 (a previous announcement had stated the ... to take participants from the basic training and fundamentals of nasal surgery through the ...
(Date:7/3/2015)... ... July 03, 2015 , ... B. E. Smith, the ... to lead a national president recruitment for Regional Care, Inc. in ... B. E. Smith has recently placed more than 1,000 healthcare executives into organizations. ...
(Date:7/3/2015)... (PRWEB) , ... July 03, 2015 , ... ... exclusively to healthcare providers, has been retained to lead a national chief ... of the top-ranked executive search firms in the healthcare industry, B. E. Smith ...
Breaking Medicine News(10 mins):Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 2Health News:RNS Announces Sessions and Speaker Lineup for the 2015 Annual Conference of the Rheumatology Nurses Society 3Health News:Study Finds Small Amounts of Asbestos May Trigger Mesothelioma in People with Genetic Mutation, According to Surviving Mesothelioma 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 2Health News:Dr. Rod J. Rohrich Announces the Dates for 2016 Dallas Rhinoplasty Symposium 3Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 2Health News:Regional Care, Inc. Retains B. E. Smith to Recruit New President 3Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 2Health News:Jane Phillips Medical Center Retains B. E. Smith to Recruit New Chief Nursing Officer 3
... ... the emerging medical travel space, announced that international medical quality authority, Dr. David Jaimovich, ... ... Satori World Medical, a leading global healthcare company specializing in the emerging medical travel ...
... smoke are at risk of lung cancer , THURSDAY, Dec. ... of malignancies caused by smoking, with a new study strengthening ... providing more bad news for people who haven,t managed to ... Epidemiology, Biomarkers & Prevention , a themed issue on tobacco, ...
... , Diabetes: A ... Hands-on Experience for All Ages , DETROIT, Dec. 3 ... seconds. On December 5, 2009, the Detroit Science Center will debut its ... that the public might have about diabetes, diabetes treatment and the role ...
... , HOUSTON, Dec. 3 Three US Oncology, Inc ... the Occupational Safety & Health category from the National ... Specialty, LP ; US Oncology Clinical & Research Pharmacy distribution ... have continuously received the Occupational Excellence Award from the national ...
... protected volunteers from virus linked to cervical cancer , WEDNESDAY, ... Cervarix protects women from infection for longer than six years, ... two types of HPV (HPV-16 and HPV-18) most commonly associated ... women, aged 15 to 25, with a normal cervical profile ...
... , Unfair Labor Practices, Protecting Donors, and ... Teamsters who work at American Red Cross (ARC) Blood ... protest unfair labor practices and problems with working conditions at ... the integrity of the blood supply, not to mention the ...
Cached Medicine News:Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 2Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 3Health News:Former Chief Medical Officer of Joint Commission International Joins Satori World Medical's Medical Quality Advisory Board 4Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 2Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 3Health News:Smoking Exposure Now Linked to Colon, Breast Cancers 4Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 2Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 3Health News:Interactive Traveling Diabetes Exhibit to Be Unveiled at Detroit Science Center 4Health News:US Oncology Celebrates Consecutive Safety 2Health News:US Oncology Celebrates Consecutive Safety 3Health News:Cervarix Proves Effective Against HPV for Over 6 Years 2Health News:Philadelphia Red Cross Blood Workers Strike to Protect Donor and Blood Safety 2
... million people are diagnosed with varicose veins ... patients never seek treament and are apprehensive ... offer them an effective alternative to conventional ... or hook phlebectomy), is considered a laborious ...
...
Inquire...
Inquire...
Medicine Products: